Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

exTra Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation

Coordinator
Klinikum Der Universitaet Regensburg, Germany
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€2.6m
Total cost
—
Partners
25 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119855

What the project is doing

In the project's own words, from its summary on CORDIS.

Organ transplantation remains the only definitive treatment for end-stage heart, lung, liver or kidney disease. Early transplant outcomes are now generally excellent, dramatically reducing patients’ mortality and morbidity. Nevertheless, transplantation still faces significant obstacles, especially long-term immunosuppression-related toxicity and chronic decline of transplant function, which are the leading causes of transplant failure.

To break these barriers, which represent a very significant societal and economic burden in the EU, there is a need for innovative therapies to lessen our reliance on conventional immunosuppression and better control non-resolving inflammation. Extracorporeal photopheresis (ECP) is now being investigated as a personalized, adjunct immunosuppressive therapy in some organ transplant settings. However, ECP is regarded as a controversial therapy, primarily because current understanding of its pharmacological actions is incomplete, but also because there remain questions about optimal manufacturing processes, quality-control and personalized clinical indications.

The exTra project asks whether a better mechanistic understanding of ECP can guide us more efficiently towards novel applications. Specifically, exTra brings together European experts in clinical transplantation, immunology, pharmaceutical development, computational biology and medical device manufacture to address key questions through a coordinated, interdisciplinary effort. exTra proposes 10 independent doctoral research projects with the ambition of providing its trainees with a comprehensive understanding of basic and translational immunology, especially relating development and licensing of new immunotherapies.

Through its research and training activities, the exTra project will contribute to scientific advancement and innovation in Europe, ultimately leading to societal and economic benefits stemming from clinical innovations in transplant immunotherapy and beyond.

Topics

Who is involved

OrganisationCityCountryRole
Klinikum Der Universitaet RegensburgRegensburgGermanyCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyAssociatedpartner
Amedes Medizinische Dienstleistungen GmbHGottingenGermanyAssociatedpartner
Friedrich-Alexander-Universitaet Erlangen-NuernbergErlangenGermanyAssociatedpartner
Limbach Medizinisches Labor Rosenheim MVZ GbRRosenheimGermanyAssociatedpartner
Universitaet RegensburgRegensburgGermanyAssociatedpartner
Universitaetsklinikum FreiburgFreiburgGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
AnilingBadalonaSpainAssociatedpartner
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Fundacion Instituto De Investigacion Marques De ValdecillaSantanderSpainAssociatedpartner
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainParticipant
Instituto De Salud Carlos IiiMadridSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Immunotech SASMarseilleFranceAssociatedpartner
Institut Gustave RoussyVillejuifFranceAssociatedpartner
Innovation Acta SRLSienaItalyAssociatedpartner
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner
King's College LondonLondonUnited KingdomAssociatedpartner
Quell Therapeutics LimitedLondonUnited KingdomAssociatedpartner
Therakos UK LtdStaines Upon ThamesUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI